The FDA has approved a genetically modified herpes virus that is injected directly into tumors as a treatment for advanced melanoma that has stopped responding to standard immunotherapy.
Tudriqev, given in combination with the immunotherapy nivolumab, received accelerated approval for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1 blocking antibody regimen. In the efficacy-evaluable group, 24.2% of patients responded, with responses lasting a median of 14.1 months.
Those numbers describe a minority of patients, and that framing is correct. This is an option for a population that had few, not a treatment expected to work for most people who receive it.
The Engineering That Turns a Virus into a Therapy
Oncolytic viral therapy uses viruses modified to replicate preferentially in cancer cells while sparing normal tissue. The virus enters tumor cells, multiplies inside them, and ruptures them from within.
That cell destruction is only half the design. When a tumor cell bursts, it releases its contents, including proteins the immune system had not previously encountered because they were hidden inside the cell. Combined with the inflammatory alarm a viral infection triggers, this can convert a tumor the immune system was ignoring into one it recognizes as a threat.
Tudriqev is built on herpes simplex virus type 1 with the neurovirulence factor ICP34.5 removed. It is engineered to express human GM-CSF, an immune signaling protein that recruits and activates immune cells, and a fusogenic glycoprotein derived from gibbon ape leukemia virus that causes infected cells to fuse with neighbors and spreads the effect further into the tumor.
The nivolumab pairing addresses the remaining obstacle. Even an immune system alerted to a tumor can be shut down by checkpoint signals the cancer exploits. Nivolumab blocks PD-1, releasing that brake. The virus supplies recognition; the checkpoint inhibitor permits the response to proceed. That division of labor is why the combination is approved for patients whose disease already progressed on PD-1 blockade alone.
The Evidence and the Conditions Attached
Approval rested on IGNYTE, an open-label, multiregional, single-arm trial. It enrolled 140 adults with stage IIIB, IIIC or IV unresectable advanced melanoma who had progressed after at least eight consecutive weeks of prior anti-PD-1 therapy. Of those, the 91 patients with at least one non-injected lesion formed the efficacy-evaluable population from which the response figures come.
That design limits what can be concluded. A single-arm trial measures how many tumors shrank and for how long. It cannot establish whether patients lived longer than they would have on other treatment, because there is no group to compare against.
The agency had declined to approve the therapy twice, issuing two complete response letters citing concerns about the single-arm design and the absence of a control group. This approval followed a third resubmission.
The FDA convened its Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, which voted 10 to 3 that the available data were evaluable and demonstrated clinically meaningful benefit.
Accelerated approval means continued licensure depends on verification of clinical benefit in a confirmatory trial. Replimune is running IGNYTE-3, a phase 3 study of the same combination. If it does not confirm benefit, the approval can be withdrawn.
The Safety Profile and the Practical Constraints
The company described treatment as well tolerated, with mostly mild-to-moderate adverse events, and FDA and company reviewers identified no new safety signals in the trial.
Several considerations follow from what this therapy is rather than from trial data. It is a live modified herpes virus, which raises the question of herpetic infection in the patient and of exposure for household members and caregivers, and it is administered by repeated injection into tumors that may sit near internal structures. Full prescribing information addresses these, and clinicians will manage them.
Those characteristics shape who can practically receive the treatment. It requires tumors that are physically accessible for injection, a facility equipped to handle a live viral product, and a household situation where exposure precautions can be followed. Patients who are severely immunocompromised, or who live with someone who is, face additional considerations that their oncologist would need to weigh.
The Access Question the Approval Does Not Answer
Replimune has launched ReplimuneConnect Plus, a patient support program covering access, reimbursement and financial assistance, which is itself an indication of the cost involved.
Insurance coverage for a newly approved therapy under accelerated approval is not automatic, and prior authorization requirements are likely. Coverage decisions for accelerated-approval products sometimes lag ordinary approvals, since payers may wait on confirmatory evidence. Administration at a facility experienced with intratumoral injection will also limit where patients can be treated, particularly outside major cancer centers.
Patients whose melanoma progresses after PD-1 blockade have had a difficult prognosis with limited options. That is the population this approval addresses, and it is the first commercially available product from a company founded in 2015 specifically to develop oncolytic immunotherapies.
Patients should discuss eligibility with their oncologist rather than seeking the therapy independently, since it applies to a specific disease setting and requires accessible tumors. Anyone whose melanoma has progressed on immunotherapy may also want to ask about clinical trials, which remain the setting where other approaches to resistance are being tested. MedicalDaily has covered laboratory work on drug resistance and a recent approval that followed years of development in an adjacent field.
Key Questions Answered
Who is Tudriqev approved for? Adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1 blocking antibody regimen. It is given in combination with nivolumab.
How does an oncolytic virus work? The modified virus replicates inside tumor cells and ruptures them. The released cell contents expose tumor proteins to the immune system, and the viral infection itself triggers an inflammatory response that can make an ignored tumor visible to immune cells.
How well did it work? 24.2% of patients in the efficacy-evaluable group had tumors shrink, with responses lasting a median of 14.1 months. The IGNYTE trial enrolled 140 patients, of whom 91 had a non-injected lesion and formed that group, and it had no comparison arm.
What does accelerated approval mean here? Continued approval depends on verification of clinical benefit in a confirmatory trial. Replimune is running IGNYTE-3, a phase 3 study. If it does not confirm benefit, approval can be withdrawn.
Why was it rejected before? The FDA issued two complete response letters citing the single-arm trial design and the lack of a control group. This approval followed a third resubmission and a 10-to-3 advisory committee vote.
What are the practical constraints? It requires tumors accessible for injection, a facility able to handle a live viral product, and a household able to follow exposure precautions, since the product is a live modified herpes virus.
What about cost? The manufacturer has launched a patient access and reimbursement support program. Coverage for accelerated-approval products is not automatic and prior authorization is likely.
